Summit Therapeutics Inc
NASDAQ:SMMT

Watchlist Manager
Summit Therapeutics Inc Logo
Summit Therapeutics Inc
NASDAQ:SMMT
Watchlist
Price: 17.49 USD 2.64%
Market Cap: 13B USD

Summit Therapeutics Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Summit Therapeutics Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Summit Therapeutics Inc
NASDAQ:SMMT
Free Cash Flow
-$142.2m
CAGR 3-Years
-25%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Free Cash Flow
$19.7B
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Free Cash Flow
$9.7B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Free Cash Flow
$13.1B
CAGR 3-Years
13%
CAGR 5-Years
5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Free Cash Flow
$3.3B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Free Cash Flow
$3.9B
CAGR 3-Years
-2%
CAGR 5-Years
20%
CAGR 10-Years
20%
No Stocks Found

Summit Therapeutics Inc
Glance View

Summit Therapeutics Inc., headquartered in Cambridge, Massachusetts, has carved a niche in the biopharmaceutical landscape with its focus on addressing serious unmet medical needs, primarily through the development of innovative antibiotics and therapies. The company gained significant attention with its efforts to combat antibiotic resistance, a global health threat. Their flagship endeavor, Ridinilazole, is an antibiotic designed to treat C. difficile infections, a prevalent and often severe bacterial infection affecting the gut. The company's proposition is simple yet impactful: develop effective treatments that not only address infections but also potentially reduce recurrence, thereby offering a better therapeutic alternative to existing solutions. Summit's business model is built around advancing their drug pipeline through rigorous clinical trials, securing regulatory approvals, and ultimately achieving commercialization either independently or through strategic partnerships. The partnerships are critical, as they allow Summit to leverage the expertise and market reach of larger pharmaceutical companies. Additionally, these alliances provide financial backing, helping offset the costly nature of drug development. Revenue is primarily driven from these collaborations through milestone payments and eventual product royalties, once their therapies hit the market. This strategic approach allows Summit to focus its resources on research and development while aligning with partners to navigate the complexities of bringing new therapies to patients globally.

SMMT Intrinsic Value
Not Available

See Also

What is Summit Therapeutics Inc's Free Cash Flow?
Free Cash Flow
-142.2m USD

Based on the financial report for Dec 31, 2024, Summit Therapeutics Inc's Free Cash Flow amounts to -142.2m USD.

What is Summit Therapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-46%

Over the last year, the Free Cash Flow growth was -85%. The average annual Free Cash Flow growth rates for Summit Therapeutics Inc have been -25% over the past three years , -46% over the past five years .

Back to Top